Silvercrest Asset Management’s Exagen XGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.61M Sell
537,870
-60,050
-10% -$232K 0.01% 550
2025
Q4
$3.64M Buy
597,920
+78,452
+15% +$714K 0.03% 470
2025
Q3
$5.71M Sell
519,468
-12,299
-2% -$109K 0.04% 410
2025
Q2
$3.71M Hold
531,767
0.02% 467
2025
Q1
$1.91M Sell
531,767
-3,250
-0.6% -$12.3K 0.01% 550
2024
Q4
$2.19M Sell
535,017
-5,871
-1% -$21.2K 0.01% 521
2024
Q3
$1.67M Sell
540,888
-3,989
-0.7% -$10.3K 0.01% 516
2024
Q2
$992K Hold
544,877
0.01% 627
2024
Q1
$866K Hold
544,877
0.01% 629
2023
Q4
$1.08M Hold
544,877
0.01% 580
2023
Q3
$1.32M Sell
544,877
-2,256
-0.4% -$5.72K 0.01% 550
2023
Q2
$1.59M Buy
547,133
+44,518
+9% +$127K 0.01% 520
2023
Q1
$1.22M Hold
502,615
0.01% 546
2022
Q4
$1.21M Sell
502,615
-4,493
-0.9% -$11.5K 0.01% 552
2022
Q3
$1.37M Buy
507,108
+11,520
+2% +$64.3K 0.01% 505
2022
Q2
$2.85M Sell
495,588
-22,029
-4% -$128K 0.02% 415
2022
Q1
$4.16M Buy
517,617
+4,727
+0.9% +$40.8K 0.03% 402
2021
Q4
$5.96M Hold
512,890
0.04% 351
2021
Q3
$6.97M Buy
512,890
+202,692
+65% +$2.69M 0.05% 326
2021
Q2
$4.65M Sell
310,198
-1,257
-0.4% -$19.3K 0.03% 401
2021
Q1
$5.45M Buy
+311,455
New +$5.55M 0.04% 364

Other funds holding XGN

Silvercrest Asset Management's XGN Position: Q1 2026 in Review

Silvercrest Asset Management reduced its Exagen (XGN) stake by 10% in Q1 2026, selling an estimated $232K and leaving 537,870 shares worth $1.61M. The position accounts for 0.01% of the portfolio, ranked #550.

Silvercrest Asset Management first reported a position in XGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $6.97M in Q3 2021. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Silvercrest Asset Management held 537,870 shares of Exagen worth $1.61M as of Q1 2026.
  • Silvercrest Asset Management sold 60,050 Exagen shares in Q1 2026, an estimated $232K.
  • Exagen made up 0.01% of Silvercrest Asset Management's portfolio in Q1 2026, its #550 holding.
  • Silvercrest Asset Management first reported a position in Exagen in Q1 2021 and has held it in 21 quarters since.
  • Silvercrest Asset Management's Exagen position peaked at $6.97M in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.